Johnson & Johnson Covid-19 vaccine is 66% effective in worldwide trials, but 85% effective against serious diseases, says the company
Rapid blood test identifies COVID-19 patients at high risk for serious diseases – the Washington University School of Medicine in St. Louis
New Jersey prioritizes cigarette smokers for COVID-19 vaccines because of their risk for serious diseases
Bionano Genomics announces the launch of its next-generation cytogenomics symposium, the biggest event yet to showcase Saphyr’s usefulness in genetic analysis for genetic diseases and cancer